The use of an oral contraceptive containing estradiol valerate and dienogest before office operative hysteroscopy: A feasibility study

Gynecological Endocrinology

Volumn 28, Issue 12, 2012, Pages 949-955

  Bifulco, Giuseppe ^a   Di Spiezio Sardo, Attilio ^a   De Rosa, Nicoletta ^a   Greco, Elena ^a   Spinelli, Marialuigia ^a   Di Carlo, Costantino ^a   Tommaselli, Giovanni A ^a   Nappi, Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Combined oral contraceptive; Dienogest; Endometrium; Estradiol valerate; Office operative hysteroscopy

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE;

ARTICLE; CASE CONTROL STUDY; ENDOMETRIUM POLYP; FEASIBILITY STUDY; FEMALE; GYNECOLOGIC SURGERY; HORMONAL THERAPY; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; NEWBORN; OFFICE OPERATIVE HYSTEROSCOPY; ORAL CONTRACEPTION; POSTOPERATIVE PAIN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UTERINE TUBE STERILIZATION; VISUAL ANALOG SCALE;

ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; DRUG COMBINATIONS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRADIOL; FEASIBILITY STUDIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYSTEROSCOPY; NANDROLONE; OPERATIVE TIME; OUTPATIENT CLINICS, HOSPITAL; PAIN, POSTOPERATIVE; PILOT PROJECTS; POLYPS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; STERILIZATION, TUBAL; UTERUS;

EID: 84870010071     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.683078     Document Type: Article

References (43)

1. Baggish MS, Barbot J, Valle RF, eds. Diagnostic and operative hysteroscopy. A text and atlas. Philadelphia: Saunders, 1988.
2. Bieber EJ, Lofer FD. Gynecologic resectoscopy. London: Blackwell Scientifc, 1995.
3. Porreca MR, Pansini N, Bettocchi S, Loverro G, Selvaggi L. Hysteroscopic polypectomy in the ofce without anesthesia. J Am Assoc Gynecol Laparosc 1996;3:S40.
4. Mazzon I, Sbiroli C. Manuale di chirurgia resettoscopica in ginecologia. Milan, Italy: Unione Tipografco-Editrice Torinase (UTET); 1997.
5. Lindheim SR, Kavic S, Shulman SV, Sauer M V. Operative hysteroscopy in the ofce setting. J Am Assoc Gynecol Laparosc 2000;7:65-69.
6. Bettocchi S, Ceci O, Di Venere R, Pansini MV, Pellegrino A, Marello F, Nappi L. Advanced operative ofce hysteroscopy without anaesthesia: analysis of 501 cases treated with a 5 Fr. bipolar electrode. Hum Reprod 2002;17:2435-2438.
7. Bettocchi S, Nappi L, Ceci O, Selvaggi L. Ofce hysteroscopy. Obstet Gynecol Clin North Am 2004;31:641-54, xi.
8. Bettocchi S, Nappi L, Ceci O, Selvaggi L. What does 'diagnostic hysteroscopy' mean today? Te role of the new techniques. Curr Opin Obstet Gynecol 2003;15:303-308.
9. Di Spiezio Sardo A, Taylor A, Tsirkas P, Mastrogamvrakis G, Sharma M, Magos A. Hysteroscopy: a technique for all? Analysis of 5, 000 outpatient hysteroscopies. Fertil Steril 2008;89:438-443.
10. Guida M, Bifulco G, Di Spiezio Sardo A, Scala M, Fernandez LM, Nappi C. Review of the safety, efcacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health 2010;2:279-290.
11. Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 2010;11:1147-1157.
12. Bettocchi S, Ceci O, Nappi L, Pontrelli G, Pinto L, Vicino M. Ofce hysteroscopic metroplasty: three "diagnostic criteria" to diferentiate between septate and bicornuate uteri. J Minim Invasive Gynecol 2007;14:324-328.
13. Guida M, Pellicano M, Zullo F, Acunzo G, Lavitola G, Palomba S, Nappi C. Outpatient operative hysteroscopy with bipolar electrode: a prospective multicentre randomized study between local anaesthesia and conscious sedation. Hum Reprod 2003;18:840-843.
14. Mencaglia L, Tantini C. GnRH agonist analogs and hysteroscopic resection of myomas. Int J Gynaecol Obstet 1993;43:285-288.
15. Parazzini F, Vercellini P, De Giorgi O, Pesole A, Ricci E, Crosignani PG. Efcacy of preoperative medical treatment in facilitating hysteroscopic endometrial resection, myomectomy and metroplasty: literature review. Hum Reprod 1998;13:2592-2597.
16. Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V, Saravelos H, Kostopoulou E, et al. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas 2004;48:125-132.
17. Gutmann JN, Corson SL. GnRH agonist therapy before myomectomy or hysterectomy. J Minim Invasive Gynecol 2005;12:529-37; quiz 528, 538.
18. Donnez J, Nisolle M. An atlas of laser operative laparoscopy and hysteroscopy. London, England: Parthenon Publishing; 1993.
19. Donnez J, Nisolle M, Grandjean P, Gillerot S, Clerckx F. [Te role of GnRH agonists in the endoscopic treatment of endometriosis and fbromyomas]. Contracept Fertil Sex 1993;21:59-62.
20. Lin B, Akiba Y, Iwata Y. One-step hysteroscopic removal of sinking submucous myoma in two infertile patients. Fertil Steril 2000;74:1035-1038.
21. Wentz AC, Jones GS, Sapp KC, King TM. Progestational activity of danazol in the human female subject. Am J Obstet Gynecol 1976;126:378-384.
22. Gonzalez-Gómez F, Merchan J, Caballero-Peregrin P, Aldama Magnet J. [Electronmicroscopical aspects of endometrial distrophy induced by oral contraceptives (author's transl)]. Reproduccion 1975;2:233-245.
23. Deligdisch L. Efects of hormone therapy on the endometrium. Mod Pathol 1993;6:94-106.
24. Sowter MC, Lethaby A, Singla AA. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Cochrane Database Syst Rev 2002;CD001124.
25. Grow DR, Iromloo K. Oral contraceptives maintain a very thin endometrium before operative hysteroscopy. Fertil Steril 2006;85:204-207.
26. Florio P, Imperatore A, Litta P, Franchini M, Calzolari S, Angioni S, Gabbanini M, et al. Te use of nomegestrol acetate in rapid preparation of endometrium before operative hysteroscopy in pre-menopausal women. Steroids 2010;75:912-917.
27. Vilos GA. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil Steril 1999;72:740-743.
28. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008;78:218-225.
29. Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436-444.
30. Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacokinetic point of view. Drugs Today (Barc). 1995; 317:499-516.
31. Oettel M, Holz C. Hybrid progestins: Te example of dienogest. In: Sitruk-Ware R, Mishell DR, editors. Progestins and antiprogestins in clinical practice. New York, NY: Marcel Dekker; 2000.
32. Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, Kato S, Mizuguchi K. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efcient pharmacokinetic profle. Steroids 2008;73:222-231.
33. Oettel M, Breitbarth H, Elger W, et al. Te pharmacological profle of dienogest. Eur J Contracept Reprod Health Care. 1999; 4 Suppl 1:2-13.
34. Lessey BA, Killam A P, Metzger DA, Haney AF, Greene GL, McCarty KS Jr. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 1988;67:334-340.
35. Mustonen MV, Isomaa VV, Vaskivuo T, Tapanainen J, Poutanen MH, Stenbäck F, Vihko RK, Vihko PT. Human 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle. J Clin Endocrinol Metab 1998;83:1319-1324.
36. Giangrande PH, McDonnell DP. Te A and B isoforms of the human progesterone receptor: two functionally diferent transcription factors encoded by a single gene. Recent Prog Horm Res 1999;54:291-313; discussion 313.
37. Sasagawa S, Shimizu Y, Kami H et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efcient pharmacokinetic profle. Steroids. 2008; 73:222-231.
38. Shimizu Y, Takeuchi T, Mita S, Mizuguchi K, Kiyono T, Inoue M, Kyo S. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 2009;15:693-701.
39. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 2011;76:60-67.
40. Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, Manhes H. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002;77:684-692.
41. Schindler AE, Christensen B, Henkel A, Oettel M, Moore C. Highdose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol 2006;22:9-17.
42. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond Engl) 2010;6:27-35.
43. Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health 2011;3:127-132.